BJC Cardiology

02/02/2023

Go Red For Women Day is the first Friday of February. The day recognizes the impact of cardiovascular disease on the lives of women and their communities.

I hope you'll join us in our efforts to raise our awareness, recognition, and treatment of heart and vascular disease, by wearing red this Friday.

Cardiovascular disease (CVD) is the #1 cause of death in men and women in the United States and in the world. Much of CVD can be avoided. And when CVD is encountered, the appropriate treatment is imperative to reduce the risk of major adverse events (heart attack, stroke, heart failure, and death), improve quality of life, and extend life.

🎉 Let's get the American party started! 🥳️

It's time to introduce the 12 heart disease and stroke survivors from across the nation who will serve as the 2023 faces of the American Heart Association’s national Go Red for Women movement. Meet your 2023 Real Women Class of Survivors:

❤️️ Naomi James, 34, born with a congenital heart defect
❤️️ Ann Ramirez Duda, 53, who received a heart transplant
❤️️ Brittany Williams, 32, who survived sudden cardiac arrest
❤️️ Yael Shvetz, 54, who survived a rare hemorrhagic stroke (brain bleed)
❤️️ Dawn Turnage, 52, who survived a mini-stroke
❤️️ Dina Pinelli, 48, who survived three widow-maker heart attacks
❤️️ Jia Wu, 30, who survived multiple mini-strokes
❤️️ Margarita Pineiro, 43, who survived spontaneous coronary artery dissection (SCAD)
❤️️ Sharell Weeams, 44, who survived sudden cardiac arrest
❤️️ Leslie Jordan, 38, who survived multiple strokes
❤️️ Ceirra Zeager, 23, who survived a heart attack
❤️️ Shemellar Davis, 46, who survived postpartum cardiomyopathy

These national ambassadors serve a one-year volunteer term representing a diverse sisterhood of survivors who actively, urgently and passionately champion our movement to eliminate the No. 1 killer of women, cardiovascular disease.

Learn more about these incredible ⤵️
http://spr.ly/61823eQXk

01/27/2023

Not sure how many groups can legitimately say they changed the local healthcare landscape in a positive way, but we are very proud to have helped bring exceptional, accessible interventional cardiovascular services to the communities in which we serve.

Parkland Health Center has opened a cardiac cath lab to provide advanced heart care for the community.

01/25/2023

The offices of Midwest Heart Institute & Guzon Cardiovascular are closed today. Stay safe!

12/22/2022

The offices are closed early today due to the inclement weather. Stay safe and please call our exchange if you need assistance.

11/02/2022

I'm pretty proud to have had the opportunity to implant the first two Impulse Dynamics Optimizer Smart Mini cardiac contractility modulation (CCM) devices not only in St. Louis but in the state of Missouri in the past week.

The device is FDA-approved to improve the symptoms, quality of life, and performance of those whose lives are significantly limited their weak heart. After implant, recipients often experience a noticeable improvement within hours and durable benefit years after implant.

If you or someone you know suffers from congestive heart failure (CHF) due to a weak heart despite maximal medical therapy, this device may be the answer to your/their hope for a better life.

To learn more and discuss whether you are an appropriate candidate for this or other heart failure treatment options, please call 6369317101 or 5737010090 to set up an appointment.

Special thanks to the whole team along each step of the way, from those who help to coordinate each procedure, to those who prepare and educate our patient before and after their procedure, to those who keep our patients as humanly safe as possible in the OR.

Not pictured: Barb Neiswander Cindy Naeger Ralph Albanese

01/29/2022

We are very proud to announce our new partnership with BJC Healthcare

Parkland Health Center has opened a cardiac cath lab to provide advanced heart care for the community.

05/07/2020

The FDA has approved a drug to treat patients with low ejection fraction congestive heart failure (CHF).

Patients with an ejection fraction less than 40% who were given this drug when added to the usual therapies for those with a weak heart were 30% less likely to be hospitalized for CHF and about 20% less likely to die.

To learn more about what is the new standard of care for CHF, come see us!

The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.